Recent progress in molecular analysis has shown that abnormal chromosome constructs cause aberrant gene expression, leading to cancer. The chromosome rearrangements so far described include deletions, insertions, translocations and inversions. Analysis of chromosomaltranslocations and inversions has attracted a great deal of attention, especially in hematological malignancies. There are two principal mechanisms of oncogene activation by translocations and inversions; proto-oncogene activation by juxtaposing genes having potent enhancer effects, like immunoglobulin genes, and formation of fusion genes encoding for oncogenic chimeric proteins (1). Representatives of the former include c-myc of t(8: 14), and cabl oft(9;22) is a good example of the latter. Interestingly, such chromosomal aberrations have been found to be specific to particular subtypes of leukemias, implying cytogenetic-clinicopathological correlations, which might allow understanding of the pathogenesis of these important malignancies. One of the most frequent chromosomal rearrangements detected in the de novo acute myelogenous leukemia (AML)is the chromosome 16 inversion [inv(16)(pl3;q22)], which has been reported to account for up to 12% of the karyotypic abnormalities found with this neoplasm (2). This abnormality is highly correlated with, but not uniformly restricted to, acute myelomonocyticleukemias with bone marroweosinophilia (5% or more of the nonerythroid cells), the French-AmericanBritish (FAB) type M4Eo (3). Of this subgroup, almost all have inv(16), del (16) See also p 327.
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The breakpoints featured in the inv(16) have recently been cloned and have been shown to involve the CBFBgene on 16q22andthzMYHll geneon 16pl3 (6, 7). CBFB codesforthe P subunit of the core binding factor (CBF), a heterodymeric transcription factor knownto bind to the enhancers of various murine leukemia viruses and to similar motifs in the enhancers of T-cell receptor (TCR) genes. MYHllencodes the smooth muscle form ofmyosinheavy chain protein. The fusion creates an in frame fusion messenger RNAconsisting of upstream CBFBfused to downstream MYHllcoding sequences, and the resultant chimeric protein has the potential for transforming activity in vitro. The mechanism of action of the invl6 protein is unknown,but the invl6 protein complex with the a subunit of CBF, which binds to the DNA,may alter the assembly of sequence specific transcription factors on adjacent sites in the enhancers of certain target genes (7). Since the cloning ofinv(16), several groups have tested and verified that the CBFB-MYH1 1 fusion is the primary molecular event associated with this inversion. Claxton et al (8) studied a series of 37 leukemic patients with either inv(16) or t(16;16) using the reverse transcriptase-polymerase chain reaction (RT-PCR) and showed all patients except one to exhibit CBFB-MYH11 fusion mRNA.Another group (9) revealed CBFB-MYH11 fusion messages in 33 of37 cases with inv(16) and in all of four t(16; 16)-containing cases. These data also indicated that the genetic consequences of rearrangements in inv( 1 6) and t( 16; 16) are identical. In addition, Marlton et al (10) reported six patients with 5'-CBFB/MYH l 1 -3' chimeric transcripts to have a deletion of the chromosome16p arm containing the exon of the 5' portion of the MYH11 gene, using fluorescence in situ hybridization (FISH), confirming that the 5'-CBFB/MYHl 1 -3' transcript, rather than the reciprocal 5'-MYHl l/CBFB-3', is the critical product for inv( 16) leukemogenesis.
Of the three related chromosome 16 rearrangements observed cytogenetically in leukemia patients, the only one that has notbeen analyzed at the molecular level is the del( 16)(q22). Usuki et al in this issue (ll) describe an AMLcase with this rearrangement, providing RT-PCRevidence of the expression of the CBFB-MYH1 1 fusion transcript. Sequence analysis of the fusion transcript demonstrated in frame fusion of 5' CBFB atposition 495 to 3' MYHllat 1201, which corresponds to one of the typical chimeric cDNAsdetected in inv(16) or t(16;16). The described data indicated that leukemia cells diagnosed as del(16)(q22) from cytogenetical analysis, contain inv(16) or t(16;16). This is the first report featuring detailed studies of del(16)(q22) at the molecular level. The findings, in line with the literature, suggest that RT-PCRand FISH molecular analyses of more patients with del( 16)(q22) or variant translocations such as the t(5; 16)(q33;q22) (12) may shed important light on the mechanisms of leukemogenesis caused by the inversion 1 6 fusion gene.
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